Palisade Bio, Inc. (PALI)
| Market Cap | 263.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.23M |
| Shares Out | 149.00M |
| EPS (ttm) | -2.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,856,894 |
| Open | 1.810 |
| Previous Close | 1.850 |
| Day's Range | 1.765 - 1.850 |
| 52-Week Range | 0.530 - 2.640 |
| Beta | 1.61 |
| Analysts | Strong Buy |
| Price Target | 13.00 (+634.46%) |
| Earnings Date | Mar 23, 2026 |
About PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufa... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for PALI stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 634.46% from the latest price.
News
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“...
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Virtual presentation scheduled for Thursday, February 26 th at 12:40 PM ET Access the webcast here Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the ...
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis
Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibroste...
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
PALI-2108 is the first and only PDE4 inhibitor in development targeting the terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD) to address signif...
Palisade Bio: Gut Prodrug For IBD With Catalysts
Palisade Bio's bull thesis centers on PALI-2108. This is a gut-targeted PDE4 prodrug aiming for local efficacy with fewer systemic PDE4 side effects. The main target indications are UC and FSCD, which...
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
Live webcast fireside chat on Thursday, December 4 th at 10:30 AM ET Carlsbad, CA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage b...
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical nee...
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutic...
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
Offering was led by B Group Capital and Columbia Threadneedle Investments with significant participation from Adage Capital Partners LP, ADAR1 Capital Management, Boxer Capital Management, Coastlands ...
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock
Carlsbad, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel t...
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
Carlsbad, CA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeuti...
Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data
PALI-2108 demonstrated favorable safety, with no serious adverse events, lab abnormalities, or EKG concerns Phase 1b data demonstrated 100% clinical response and promising signals regarding the effica...
Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) an...
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical ne...
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel th...
Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference
– Video webcast now available on-demand Carlsbad, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceut...